Cannabis Rescheduling Reaches Its Final Stage: Post-Hearing Briefs Due August 17

The U.S. Drug Enforcement Administration's formal hearing on rescheduling marijuana from Schedule I to Schedule III of the Controlled Substances Act concluded on July 15, 2026, after 11 days of testimony. Chief Administrative Law Judge Derek Julius set an August 17 deadline for all parties to submit post-hearing briefs and closing arguments. After the briefs are filed, he will issue his recommendation to the DEA Administrator, who holds the final decision authority.

How the Process Reached This Stage

The Department of Justice first proposed the Schedule III transfer in May 2024, consistent with the Department of Health and Human Services' finding that marijuana has a currently accepted medical use. The proposal moved through review and procedural delays through 2024 and 2025. In December 2025, President Trump issued an executive order directing the Attorney General to expedite the rescheduling process. In April 2026, Acting Attorney General Todd Blanche immediately placed FDA-approved marijuana products and products under qualifying state medical licenses into Schedule III, and ordered the expedited hearing that ran from June 29 through July 15.

What Happened at the Hearing

The DEA itself was the proponent of the Schedule III rule — a notable reversal after decades of federal prohibition posture. An FDA controlled-substances official acknowledged accepted medical uses and compared cannabis's safety profile favorably to alcohol and opioids. Opposing testimony came from groups including Smart Approaches to Marijuana and several states, focusing on workplace safety, impaired driving, and the sufficiency of the medical evidence.

What Schedule III Would — and Would Not — Do

Schedule III is not legalization. It would primarily change the federal tax treatment of state-licensed operators by removing the application of Section 280E of the Internal Revenue Code, improve research access, and soften the federal regulatory posture toward the industry. State licensing regimes would remain the operating framework. The change would not create a federal commercial cannabis market or preempt state rules.

Practical Implications for Cannabis Operators

Businesses should model Section 280E relief scenarios now, review corporate structures that were built around 280E workarounds, and prepare for a different federal posture on research, banking, and compliance. The ALJ's recommendation after August 17 is the next procedural milestone, but the timing of any final DEA action is not fixed.

Sources

• DEA.gov — Marijuana Rescheduling Regulatory Actions
• DEA.gov — Interim final rule and hearing notice, June 25, 2026
• Federal Register — Notice of Hearing, April 28, 2026
• U.S. Department of Justice — April 24, 2026 press release

Cogent Law advises cannabis operators on regulatory strategy, corporate structure, and compliance. Contact us to prepare for a Schedule III transition.